130 related articles for article (PubMed ID: 23564228)
21. Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience.
Nobili S; Lavacchi D; Perrone G; Vicini G; Tassi R; Landini I; Grosso A; Roviello G; Mazzanti R; Santomaggio C; Mini E
Oncol Res; 2020 May; 28(3):237-248. PubMed ID: 31806078
[TBL] [Abstract][Full Text] [Related]
22. Mitomycin C, vinorelbine, carboplatin plus granulocyte-macrophage colony-stimulating factor for treatment of advanced non-small cell lung carcinoma.
Hejna M; Kornek GV; Raderer M; Marosi L; Schneeweiss B; Greul R; Weinländer G; Valencak J; Huber H; Scheithauer W
Oncology; 1998; 55(6):538-42. PubMed ID: 9778620
[TBL] [Abstract][Full Text] [Related]
23. Induction chemotherapy with cisplatin, vinorelbine, and mitomycin-C followed by surgery for patients with pathologic N2 non-small-cell lung cancer.
Akamine S; Nakamura Y; Oka T; Soda H; Taniguchi H; Fukuda M; Minami H; Nagashima S; Ashizawa K; Goya T; Oka M; Kohno S; Tagawa T; Nagayasu T;
Clin Lung Cancer; 2008 Jan; 9(1):44-50. PubMed ID: 18282358
[TBL] [Abstract][Full Text] [Related]
24. Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study.
Cremonesi M; Mandalà M; Cazzaniga M; Rezzani C; Gambera M; Barni S
Oncology; 2003; 64(2):97-101. PubMed ID: 12566905
[TBL] [Abstract][Full Text] [Related]
25. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V
Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).
Baldini E; Tibaldi C; Ardizzoni A; Salvati F; Antilli A; Portalone L; Barbera S; Romano F; De Marinis F; Migliorino MR; Noseda MA; Borghini U; Crippa M; Ferrara G; Raimondi M; Fioretti M; Bandera M; Pennucci MC; Galeasso G; Cacciani GC; Lepidini G; Sunseri G; Lanfranco C; Rinaldi M; Rosso R
Br J Cancer; 1998 Jun; 77(12):2367-70. PubMed ID: 9649160
[TBL] [Abstract][Full Text] [Related]
27. Weekly vinorelbine and paclitaxel in older patients with advanced non-small cell lung cancer: A phase II Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Huerter MM; Meza JL; Copur MS; Tolentino A; Marr AS; Ketcham M; DeSpiegelaere H; Kruse S; Kos ME; Swenson K; Radniecki SE; Kessinger A; Ganti AK
J Geriatr Oncol; 2017 Jan; 8(1):18-22. PubMed ID: 27491498
[TBL] [Abstract][Full Text] [Related]
28. Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC--a phase II trial.
Babiak A; Hetzel J; Godde F; König HH; Pietsch M; Hetzel M
Br J Cancer; 2007 Apr; 96(7):1052-6. PubMed ID: 17353918
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
Douillard JY; Rosell R; De Lena M; Carpagnano F; Ramlau R; Gonzáles-Larriba JL; Grodzki T; Pereira JR; Le Groumellec A; Lorusso V; Clary C; Torres AJ; Dahabreh J; Souquet PJ; Astudillo J; Fournel P; Artal-Cortes A; Jassem J; Koubkova L; His P; Riggi M; Hurteloup P
Lancet Oncol; 2006 Sep; 7(9):719-27. PubMed ID: 16945766
[TBL] [Abstract][Full Text] [Related]
30. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
Platania M; Pasini F; Porcu L; Boeri M; Verderame F; Modena Y; Del Conte A; Nichetti F; Garassino MC; Martinetti A; Sottotetti E; Cavanna L; Vattemi E; Pozzessere D; Bertolini A; Irtelli L; Verri C; Sozzi G; Proto C; Pastorino U; Torri V; Fraccon AP; Spinnato F; Signorelli D; Lo Russo G; Tuzi A; Gallucci R; Cinieri S; Mencoboni M; Antonelli P; Giacomelli L; de Braud F
Lung Cancer; 2019 Jun; 132():17-23. PubMed ID: 31097088
[TBL] [Abstract][Full Text] [Related]
31. Benefit of adjuvant chemotherapy for resected pathologic N1 non-small cell lung cancer is unrecognized: A subgroup analysis of the JBR10 trial.
Toubat O; Ding L; Ding K; Wightman SC; Atay SM; Harano T; Kim AW; David EA
Semin Thorac Cardiovasc Surg; 2024 Summer; 36(2):261-270. PubMed ID: 36272526
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
Rosell R; Robinet G; Szczesna A; Ramlau R; Constenla M; Mennecier BC; Pfeifer W; O'Byrne KJ; Welte T; Kolb R; Pirker R; Chemaissani A; Perol M; Ranson MR; Ellis PA; Pilz K; Reck M
Ann Oncol; 2008 Feb; 19(2):362-9. PubMed ID: 17947225
[TBL] [Abstract][Full Text] [Related]
33. [Combined Chemotherapy with Vinorelbine and Ifosfamide as Third-line Treatment and Beyond of Advanced Non-small Cell Lung Cancer].
Zhou Y; Xu Y; Zhao J; Zhong W; Wang M
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):351-7. PubMed ID: 26104891
[TBL] [Abstract][Full Text] [Related]
34. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
Winton T; Livingston R; Johnson D; Rigas J; Johnston M; Butts C; Cormier Y; Goss G; Inculet R; Vallieres E; Fry W; Bethune D; Ayoub J; Ding K; Seymour L; Graham B; Tsao MS; Gandara D; Kesler K; Demmy T; Shepherd F; ;
N Engl J Med; 2005 Jun; 352(25):2589-97. PubMed ID: 15972865
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Katsaounis P; Kotsakis A; Agelaki S; Kontopodis E; Agelidou A; Kentepozidis N; Vamvakas L; Christopoulou A; Karachaliou N; Hatzidaki D; Georgoulias V
Cancer Chemother Pharmacol; 2015 Apr; 75(4):821-7. PubMed ID: 25702051
[TBL] [Abstract][Full Text] [Related]
36. Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
Ouyang X; Shi M; Jie F; Bai Y; Shen P; Yu Z; Wang X; Huang C; Tao M; Wang Z; Xie C; Wu Q; Shu Y; Han B; Zhang F; Zhang Y; Hu C; Ma X; Liang Y; Wang A; Lu B; Shi Y; Chen J; Zhuang Z; Wang J; Huang J; Wang C; Bai C; Zhou X; Li Q; Chen F; Yu H; Feng J
Invest New Drugs; 2018 Apr; 36(2):315-322. PubMed ID: 29134432
[TBL] [Abstract][Full Text] [Related]
37. Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study.
O'Brien ME; Szczesna A; Karnicka H; Zatloukal P; Eisen T; Hartmann W; Kasan P; Longerey B; Lefresne F
Ann Oncol; 2004 Jun; 15(6):921-7. PubMed ID: 15151949
[TBL] [Abstract][Full Text] [Related]
38. Mitomycin C etoposide and vinorelbine (MEV II) in the treatment of metastatic stage IV non small cell lung cancer.
Gridelli C; Rossi A; Palazzolo G; Pepe R; Airoma G; Incoronato P; Bianco AR
Tumori; 1994 Apr; 80(2):128-30. PubMed ID: 8016903
[TBL] [Abstract][Full Text] [Related]
39. Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.
Fu P; Pennell NA; Sharma N; Yi Q; Dowlati A
Rev Recent Clin Trials; 2017; 12(1):51-58. PubMed ID: 27633965
[TBL] [Abstract][Full Text] [Related]
40. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
Kudoh S; Takeda K; Nakagawa K; Takada M; Katakami N; Matsui K; Shinkai T; Sawa T; Goto I; Semba H; Seto T; Ando M; Satoh T; Yoshimura N; Negoro S; Fukuoka M
J Clin Oncol; 2006 Aug; 24(22):3657-63. PubMed ID: 16877734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
